Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 1483873, 11 pages
https://doi.org/10.1155/2017/1483873
Review Article

Current Therapeutic Options for Heart Failure in Elderly Patients

Cardiology and Arrhythmology Clinic, Department of Biomedical Sciences and Public Health, University Hospital “Ospedali Riuniti”, Marche Polytechnic University, Ancona, Italy

Correspondence should be addressed to F. Guerra

Received 14 August 2017; Revised 25 October 2017; Accepted 29 October 2017; Published 15 November 2017

Academic Editor: Natale Daniele Brunetti

Copyright © 2017 F. Guerra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Akita, T. Kohno, S. Kohsaka et al., “Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival,” International Journal of Cardiology, vol. 235, pp. 162–168, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Komajda, O. Hanon, M. Hochadel et al., “Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I,” European Heart Journal, vol. 28, no. 11, pp. 1310–1318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Komajda, S. D. Anker, M. R. Cowie et al., “Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: Data from the QUALIFY global survey,” European Journal of Heart Failure, vol. 18, no. 5, pp. 514–522, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Cherubini, J. Oristrell, X. Pla et al., “The persistent exclusion of older patients from ongoing clinical trials regarding heart failure,” JAMA Internal Medicine, vol. 171, no. 6, pp. 550–556, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Cioffi, C. Stefenelli, L. Tarantini, and C. Opasich, “Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients >70 years of age with recently diagnosed systolic heart failure,” American Journal of Cardiology, vol. 92, no. 2, pp. 166–172, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. W. Rich, F. McSherry, W. O. Williford, and S. Yusuf, “Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: The DIG study,” Journal of the American College of Cardiology, vol. 38, no. 3, pp. 806–813, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Cohen-Solal, J. J. V. McMurray, K. Swedberg et al., “Benefits and safety of candesartan treatment in heart failure are independent of age: Insights from the Candesartan in heart failure - Assessment of reduction in mortality and morbidity programme,” European Heart Journal, vol. 29, no. 24, pp. 3022–3028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. D. Sin and F. A. McAlister, “The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure,” American Journal of Medicine, vol. 113, no. 8, pp. 650–656, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Kramer, L. H. Curtis, C. S. Dupree et al., “Comparative effectiveness of β-blockers in elderly patients with heart failure,” JAMA Internal Medicine, vol. 168, no. 22, pp. 2422–2428, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Segev and Y. A. Mekori, “The Cardiac Insufficiency Bisoprolol Study II,” The Lancet, vol. 353, no. 9161, article 1361, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Packer, A. J. S. Coats, M. B. Fowler et al., “Effect of carvedilol on survival in severe chronic heart failure,” The New England Journal of Medicine, vol. 344, no. 22, pp. 1651–1658, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. P. A. Poole-Wilson, K. Swedberg, J. G. F. Cleland et al., “Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial,” The Lancet, vol. 362, no. 9377, pp. 7–13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. “Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF),” The Lancet, vol. 353, no. 9169, pp. 2001–2007, 1999. View at Publisher · View at Google Scholar
  14. M. D. Flather, M. C. Shibata, A. J. S. Coats et al., “Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS),” European Heart Journal, vol. 26, no. 3, pp. 215–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Cohen-Solal, D. Kotecha, D. J. Van Veldhuisen et al., “Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: Insights from the SENIORS trial,” European Journal of Heart Failure, vol. 11, no. 9, pp. 872–880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC,” European Journal of Heart Failure, vol. 18, no. 8, pp. 891–975, 2016. View at Google Scholar
  17. E. P. Havranek, F. Abrams, E. Stevens, and K. Parker, “Determinants of mortality in elderly patients with heart failure: The role of angiotensin-converting enzyme inhibitors,” JAMA Internal Medicine, vol. 158, no. 18, pp. 2024–2028, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Køber, C. Torp-Pedersen, J. E. Carlsen et al., “A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 333, no. 25, pp. 1670–1676, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators, “Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure,” The Lancet, vol. 342, no. 8875, pp. 821–828, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Packer, P. A. Poole-Wilson, P. W. Armstrong et al., “Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure,” Circulation, vol. 100, no. 23, pp. 2312–2318, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. The SOLVD Investigators, “Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure,” The New England Journal of Medicine, vol. 325, no. 5, pp. 293–302, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Pfeffer, E. Braunwald, L. A. Moyé et al., “Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial,” The New England Journal of Medicine, vol. 327, no. 10, pp. 669–677, 1992. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Pfeffer, K. Swedberg, C. B. Granger et al., “Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme,” The Lancet, vol. 362, no. 9386, pp. 759–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. J. N. Cohn and G. Tognoni, “A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure,” The New England Journal of Medicine, vol. 345, no. 23, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. B. Pitt, P. A. Poole-Wilson, R. Segal et al., “Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the losartan heart failure survival study ELITE II,” The Lancet, vol. 355, no. 9215, pp. 1582–1587, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. A. Konstam, J. D. Neaton, K. Dickstein et al., “Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial,” The Lancet, vol. 374, no. 9704, pp. 1840–1848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. J. V. McMurray, M. Packer, A. S. Desai et al., “Angiotensin-neprilysin inhibition versus enalapril in heart failure,” The New England Journal of Medicine, vol. 371, no. 11, pp. 993–1004, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. P. S. Jhund, M. Fu, E. Bayram et al., “Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF,” European Heart Journal, vol. 36, no. 38, pp. 2576–2584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Zannad, J. J. V. McMurray, H. Krum et al., “Eplerenone in patients with systolic heart failure and mild symptoms,” The New England Journal of Medicine, vol. 364, no. 1, pp. 11–21, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Tavazzi, K. Swedberg, M. Komajda et al., “Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: Insights from the SHIFT study,” European Journal of Heart Failure, vol. 15, no. 11, pp. 1296–1303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Swedberg, M. Komajda, M. Böhm et al., “Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study,” The Lancet, vol. 376, no. 9744, pp. 875–885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Ahmed, M. W. Rich, T. E. Love et al., “Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial,” European Heart Journal, vol. 27, no. 2, pp. 178–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Garg, R. Gorlin, T. Smith, and S. Yusuf, “The effect of digoxin on mortality and morbidity in patients with heart failure,” The New England Journal of Medicine, vol. 336, no. 8, pp. 525–533, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Zinman, C. Wanner, J. M. Lachin et al., “Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes,” The New England Journal of Medicine, vol. 373, no. 22, pp. 2117–2128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Fitchett, B. Zinman, C. Wanner et al., “Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial,” European Heart Journal, vol. 37, no. 19, pp. 1526–1534, 2016. View at Publisher · View at Google Scholar
  38. P. Ponikowski, A. A. Voors, S. D. Anker et al., “ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 37, no. 27, pp. 2129–2200, 2016. View at Google Scholar
  39. B. D. Westenbrink, R. A. De Boer, A. A. Voors, W. H. Van Gilst, and D. J. Van Veldhuisen, “Anemia in chronic heart failure: Etiology and treatment options,” Current Opinion in Cardiology, vol. 23, no. 2, pp. 141–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Von Haehling, M. S. Anker, E. A. Jankowska, P. Ponikowski, and S. D. Anker, “Anemia in chronic heart failure: Can we treat? What to treat?” Heart Failure Reviews, vol. 17, no. 2, pp. 203–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Mozaffarian, R. Nye, and W. C. Levy, “Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE),” Journal of the American College of Cardiology, vol. 41, no. 11, pp. 1933–1939, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. D. O. Okonko, A. Grzeslo, T. Witkowski et al., “Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. FERRIC-HF: A Randomized, Controlled, Observer-Blinded Trial,” Journal of the American College of Cardiology, vol. 51, no. 2, pp. 103–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. S. D. Anker, J. C. Colet, and G. Filippatos, “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. J. Moss, W. Zareba, W. Jackson Hall et al., “Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction,” The New England Journal of Medicine, vol. 346, no. 12, pp. 877–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Kadish, A. Dyer, J. P. Daubert et al., “Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2151–2158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. G. H. Bardy, K. L. Lee, D. B. Mark et al., “Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure,” The New England Journal of Medicine, vol. 352, no. 3, pp. 225–237, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Køber, J. J. Thune, J. C. Nielsen et al., “Defibrillator implantation in patients with nonischemic systolic heart failure,” The New England Journal of Medicine, vol. 375, no. 13, pp. 1221–1230, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. A. E. Buxton, K. L. Lee, J. D. Fisher, M. E. Josephson, E. N. Prystowsky, and G. Hafley, “A randomized study of the prevention of sudden death in patients with coronary artery disease,” The New England Journal of Medicine, vol. 341, no. 25, pp. 1882–1890, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. S. H. Hohnloser, K. H. Kuck, P. Dorian et al., “Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction,” The New England Journal of Medicine, vol. 351, no. 24, pp. 2481–2488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Santangeli, L. Di Biase, A. Dello Russo et al., “Meta-analysis: Age and effectiveness of prophylactic implantable cardioverter-defibrillators,” Annals of Internal Medicine, vol. 153, no. 9, pp. 592–599, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. H. Kong, S. M. Al-Khatib, G. D. Sanders, V. Hasselblad, and E. D. Peterson, “Use of implantable cardioverter-defibrillators for primary prevention in older patients: A systematic literature review and meta-analysis,” Cardiology Journal, vol. 18, no. 5, pp. 503–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Earley, R. Persson, A. C. Garlitski, E. M. Balk, and K. Uhlig, “Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups: A systematic review,” Annals of Internal Medicine, vol. 160, no. 2, pp. 111–121, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Zareba, H. Klein, I. Cygankiewicz et al., “Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT),” Circulation, vol. 123, no. 10, pp. 1061–1072, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Strimel, S. Koplik, H. Robert Chen, J. Song, and S. K. S. Huang, “Safety and effectiveness of primary prevention cardioverter defibrillators in octogenarians,” Pacing and Clinical Electrophysiology, vol. 34, no. 7, pp. 900–906, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Guerra, M. Flori, P. Bonelli, F. Patani, and A. Capucci, “Electrical storm and heart failure worsening in implantable cardiac defibrillator patients,” Europace, vol. 17, no. 2, pp. 247–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Guerra, P. Palmisano, G. Dell'Era et al., “Implantable cardioverter-defibrillator programming and electrical storm: Results of the OBSERVational registry On long-term outcome of ICD patients (OBSERVO-ICD),” Heart Rhythm, vol. 13, no. 10, pp. 1987–1992, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Brignole, A. Auricchio, G. Baron-Esquivias et al., “2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA),” Europace, vol. 15, no. 8, pp. 1070–118, 2013. View at Google Scholar
  58. M. R. Bristow, L. A. Saxon, J. Boehmer et al., “Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2140–2227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. J. G. F. Cleland, J.-C. Daubert, E. Erdmann et al., “The effect of cardiac resynchronization on morbidity and mortality in heart failure,” The New England Journal of Medicine, vol. 352, no. 15, pp. 1539–1549, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. A. S. L. Tang, G. A. Wells, M. Talajic et al., “Cardiac-resynchronization therapy for mild-to-moderate heart failure,” The New England Journal of Medicine, vol. 363, no. 25, pp. 2385–2395, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. L. Higgins, J. D. Hummel, I. K. Niazi et al., “Cardiac Resynchronization Therapy for the Treatment of Heart Failure in Patients with Intraventricular Conduction Delay and Malignant Ventricular Tachyarrhythmias,” Journal of the American College of Cardiology, vol. 42, no. 8, pp. 1454–1459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Guerra, P. Palmisano, G. Dell’Era et al., “Cardiac resynchronization therapy and electrical storm: results of the OBSERVational registry on long-term outcome of ICD patients (OBSERVO-ICD),” EP Europace, 2017. View at Publisher · View at Google Scholar
  63. J. Kron, J. M. Aranda Jr., W. M. Miles et al., “Benefit of cardiac resynchronization in elderly patients: Results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials,” Journal of Interventional Cardiac Electrophysiology, vol. 25, no. 2, pp. 91–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Penn, I. Goldenberg, A. J. Moss et al., “Improved outcome with preventive cardiac resynchronization therapy in the elderly: A MADIT-CRT substudy,” Journal of Cardiovascular Electrophysiology, vol. 22, no. 8, pp. 892–897, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Brambatti, F. Guerra, M. V. Matassini et al., “Cardiac resynchronization therapy improves ejection fraction and cardiac remodelling regardless of patients' age,” Europace, vol. 15, no. 5, pp. 704–710, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. Feldman D., S. V. Pamboukian, J. J. Teuteberg et al., “The 2013 international society for heart and lung transplantation guidelines for mechanical circulatory support: executive summary,” The Journal of Heart and Lung Transplantation, vol. 32, no. 2, pp. 157–187, 2013. View at Google Scholar
  67. J. K. Kirklin, D. C. Naftel, F. D. Pagani et al., “Seventh INTERMACS annual report: 15,000 patients and counting,” The Journal of Heart and Lung Transplantation, vol. 34, no. 12, pp. 1495–1504, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. J. F. Lampropulos, N. Kim, Y. Wang et al., “Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004-2011,” Open Heart, vol. 1, no. 1, Article ID e000109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. M. R. Mehra, J. Kobashigawa, R. Starling et al., “Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006,” The Journal of Heart and Lung Transplantation, vol. 25, no. 9, pp. 1024–1042, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Levy, S. Kenchaiah, M. Glarson et al., “Long-term trends in the incidence of and survival with heart failure,” The New England Journal of Medicine, vol. 347, no. 18, pp. 1397–1402, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. E. A. Rose, A. C. Gelijns, A. J. Moskowitz et al., “Long-term use of a left ventricular assist device for end-stage heart failure,” The New England Journal of Medicine, vol. 345, no. 20, pp. 1435–1443, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. J. K. Kirklin, D. C. Naftel, F. D. Pagani et al., “Sixth INTERMACS annual report: a 10,000-patient database,” The Journal of Heart and Lung Transplantation, vol. 33, no. 6, pp. 555–564, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. W. L. Holman, R. L. Kormos, D. C. Naftel et al., “Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study,” The Journal of Heart and Lung Transplantation, vol. 28, no. 1, pp. 44–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. M. J. Jurmann, Y. Weng, T. Drews, M. Pasic, E. Hennig, and R. Hetzer, “Permanent mechanical circulatory support in patients of advanced age,” European Journal of Cardio-Thoracic Surgery, vol. 25, no. 4, pp. 610–618, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. R. A. Sorabella, H. Yerebakan, R. Walters et al., “Comparison of outcomes after heart replacement therapy in patients over 65 years old,” The Annals of Thoracic Surgery, vol. 99, no. 2, pp. 582–588, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. A. N. Rosenbaum, R. John, K. K. Liao et al., “Survival in elderly patients supported with continuous flow left ventricular assist device as bridge to transplantation or destination therapy,” Journal of Cardiac Failure, vol. 20, no. 3, pp. 161–167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. E. B. Lushaj, A. Badami, S. Osaki et al., “Impact of age on outcomes following continuous-flow left ventricular assist device implantation,” Interactive CardioVascular and Thoracic Surgery, vol. 20, no. 6, pp. 743–748, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. J. H. Kim, R. Singh, F. D. Pagani et al., “Ventricular Assist Device Therapy in Older Patients With Heart Failure: Characteristics and Outcomes,” Journal of Cardiac Failure, vol. 22, no. 12, pp. 981–987, 2016. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Atluri, A. B. Goldstone, D. M. Kobrin et al., “Ventricular assist device implant in the elderly is associated with increased, but respectable risk: A multi-institutional study,” The Annals of Thoracic Surgery, vol. 96, no. 1, pp. 141–147, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. V. Mantegazza, R. Badagliacca, S. Nodari et al., “Management of heart failure in the new era: The role of scores,” Journal of Cardiovascular Medicine, vol. 17, no. 8, pp. 569–580, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. E. S. Ketchum, A. J. Moorman, D. P. Fishbein et al., “Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement,” The Journal of Heart and Lung Transplantation, vol. 29, no. 9, pp. 1021–1025, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Cowger, K. Sundareswaran, J. G. Rogers et al., “Predicting survival in patients receiving continuous flow left ventricular assist devices: The Heartmate II risk score,” Journal of the American College of Cardiology, vol. 61, no. 3, pp. 313–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. J. A. Yang, T. S. Kato, B. P. Shulman et al., “Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system,” The Journal of Heart and Lung Transplantation, vol. 31, no. 6, pp. 601–610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. T. Jaarsma, J. M. Beattie, M. Ryder et al., “Palliative care in heart failure: A position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology,” European Journal of Heart Failure, vol. 11, no. 5, pp. 433–443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. L. T. Braun, K. L. Grady, J. S. Kutner et al., “Palliative Care and Cardiovascular Disease and Stroke: A Policy Statement from the American Heart Association/American Stroke Association,” Circulation, vol. 134, no. 11, pp. e198–e225, 2016. View at Publisher · View at Google Scholar · View at Scopus